vs
MARINEMAX INC（HZO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是MARINEMAX INC的1.2倍（$622.0M vs $527.4M），Royalty Pharma plc同比增速更快（4.8% vs -16.5%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -16.6%）
MarineMax Inc.是美国头部休闲船舶及游艇零售商，主营全新及二手休闲船艇销售，同时提供船舶维保、金融服务、保险、游艇租赁及航海主题活动等配套服务，覆盖北美市场的私人航海爱好者群体。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
HZO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$527.4M
营收增速更快
RPRX
高出21.3%
-16.5%
两年增速更快
RPRX
近两年复合增速
-16.6%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $527.4M | $622.0M |
| 净利润 | — | $214.2M |
| 毛利率 | 34.4% | — |
| 营业利润率 | 2.1% | 62.4% |
| 净利率 | — | 34.4% |
| 营收同比 | -16.5% | 4.8% |
| 净利润同比 | — | 2.9% |
| 每股收益（稀释后） | $0.14 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HZORPRX
| Q1 26 | $527.4M | — | ||
| Q4 25 | $505.2M | $622.0M | ||
| Q3 25 | $552.2M | $609.3M | ||
| Q2 25 | $657.2M | $578.7M | ||
| Q1 25 | $631.5M | $568.2M | ||
| Q4 24 | $468.5M | $593.6M | ||
| Q3 24 | $563.1M | $564.7M | ||
| Q2 24 | $757.7M | $537.3M |
净利润HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | $-7.9M | $214.2M | ||
| Q3 25 | $-851.0K | $288.2M | ||
| Q2 25 | $-52.1M | $30.2M | ||
| Q1 25 | $3.3M | $238.3M | ||
| Q4 24 | $18.1M | $208.2M | ||
| Q3 24 | $4.0M | $544.0M | ||
| Q2 24 | $31.6M | $102.0M |
毛利率HZORPRX
| Q1 26 | 34.4% | — | ||
| Q4 25 | 31.8% | — | ||
| Q3 25 | 34.7% | — | ||
| Q2 25 | 30.4% | — | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 36.2% | — | ||
| Q3 24 | 34.3% | — | ||
| Q2 24 | 32.0% | — |
营业利润率HZORPRX
| Q1 26 | 2.1% | — | ||
| Q4 25 | 1.0% | 62.4% | ||
| Q3 25 | 2.5% | 70.1% | ||
| Q2 25 | -6.3% | 36.3% | ||
| Q1 25 | 3.6% | 94.0% | ||
| Q4 24 | 8.3% | 60.9% | ||
| Q3 24 | 4.8% | — | ||
| Q2 24 | 8.1% | 50.2% |
净利率HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | -1.6% | 34.4% | ||
| Q3 25 | -0.2% | 47.3% | ||
| Q2 25 | -7.9% | 5.2% | ||
| Q1 25 | 0.5% | 41.9% | ||
| Q4 24 | 3.9% | 35.1% | ||
| Q3 24 | 0.7% | 96.3% | ||
| Q2 24 | 4.2% | 19.0% |
每股收益（稀释后）HZORPRX
| Q1 26 | $0.14 | — | ||
| Q4 25 | $-0.36 | $0.49 | ||
| Q3 25 | $0.08 | $0.67 | ||
| Q2 25 | $-2.42 | $0.07 | ||
| Q1 25 | $0.14 | $0.55 | ||
| Q4 24 | $0.77 | $0.46 | ||
| Q3 24 | $0.17 | $1.21 | ||
| Q2 24 | $1.37 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.1M | $618.7M |
| 总债务越低越好 | $338.7M | $9.0B |
| 股东权益账面价值 | — | $9.7B |
| 总资产 | $2.4B | $19.6B |
| 负债/权益比越低杠杆越低 | — | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资HZORPRX
| Q1 26 | $189.1M | — | ||
| Q4 25 | $164.6M | $618.7M | ||
| Q3 25 | $170.4M | $938.9M | ||
| Q2 25 | $151.0M | $631.9M | ||
| Q1 25 | $203.5M | $1.1B | ||
| Q4 24 | $145.0M | $929.0M | ||
| Q3 24 | $224.3M | $950.1M | ||
| Q2 24 | $242.4M | $1.8B |
总债务HZORPRX
| Q1 26 | $338.7M | — | ||
| Q4 25 | — | $9.0B | ||
| Q3 25 | $393.2M | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | — | $7.6B | ||
| Q3 24 | $391.2M | $7.6B | ||
| Q2 24 | — | $7.6B |
股东权益HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | $932.8M | $9.7B | ||
| Q3 25 | $937.2M | $9.6B | ||
| Q2 25 | $940.5M | $9.5B | ||
| Q1 25 | $993.4M | $9.8B | ||
| Q4 24 | $993.5M | $10.3B | ||
| Q3 24 | $975.8M | $10.3B | ||
| Q2 24 | $967.6M | $9.8B |
总资产HZORPRX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $19.6B | ||
| Q3 25 | $2.5B | $19.3B | ||
| Q2 25 | $2.5B | $18.3B | ||
| Q1 25 | $2.7B | $17.6B | ||
| Q4 24 | $2.6B | $18.2B | ||
| Q3 24 | $2.6B | $18.0B | ||
| Q2 24 | $2.6B | $17.7B |
负债/权益比HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.92× | ||
| Q3 25 | 0.42× | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | 0.40× | 0.74× | ||
| Q2 24 | — | 0.78× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | $16.9M | $827.1M | ||
| Q3 25 | $61.5M | $702.6M | ||
| Q2 25 | $84.9M | $364.0M | ||
| Q1 25 | $72.5M | $596.1M | ||
| Q4 24 | $-146.1M | $742.5M | ||
| Q3 24 | $-782.0K | $703.6M | ||
| Q2 24 | $86.3M | $658.2M |
自由现金流HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | $8.3M | — | ||
| Q3 25 | $48.0M | — | ||
| Q2 25 | $68.5M | — | ||
| Q1 25 | $59.8M | — | ||
| Q4 24 | $-164.4M | — | ||
| Q3 24 | $-17.5M | — | ||
| Q2 24 | $71.1M | — |
自由现金流率HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 9.5% | — | ||
| Q4 24 | -35.1% | — | ||
| Q3 24 | -3.1% | — | ||
| Q2 24 | 9.4% | — |
资本支出强度HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 2.0% | — | ||
| Q4 24 | 3.9% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 2.0% | — |
现金转化率HZORPRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | 21.97× | 2.50× | ||
| Q4 24 | -8.09× | 3.57× | ||
| Q3 24 | -0.20× | 1.29× | ||
| Q2 24 | 2.74× | 6.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HZO
| Retail Operations | $525.3M | 100% |
| Product Manufacturing | $23.7M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
